Introduction
Rituximab has been administered before PBSC mobilization to purge the PBSC product of lymphoma cells for subsequent autologous hematopoietic SCT (AHSCT). Some nonrandomized studies have suggested that rituximab administration before PBSC mobilization may adversely influence PBSC yield and delay engraftment, 1,2 but others have detected no significant impact on either. [3] [4] [5] [6] We conducted a prospective, randomized trial of PBSC mobilization using etoposide and G-CSF with or without rituximab, to determine if its addition would adversely affect CD34 þ PBSC yield and hematopoietic recovery after AHSCT in patients with non-Hodgkin's lymphoma.
Patients and methods
Patients aged 18 years and older, with B-cell nonHodgkin's lymphoma, who were candidates for AHSCT were invited to participate in the trial. Adequate organ function, including cardiac ejection fraction 445%, diffusing lung capacity for carbon dioxide (DLCO) X45% predicted and serum creatinine o2.0 mg/100 ml was required. Patients were also required to have a WBC X3000/ml, ANC X1500/ml, platelet count 4100 000/ml and Hb 48.5 g/100 ml. There was no restriction for BM involvement or extent of earlier therapy. Patients were excluded if they had received rituximab within 8 weeks of registration. The study was approved by the Institutional Review Board and all patients were required to provide signed informed consent. After screening, patients were randomized in blocks of four to receive one of two mobilization regimens (MRs). The standard arm (VPG) consisted of etoposide (VP-16) 2 g/m 2 i.v. over 4 h on day 0 followed by G-CSF 10 mg/kg s.c. daily starting on day 2, 7 the standard regimen at the Cleveland Clinic for many years. The experimental arm (RVPG) included rituximab 375 mg/m 2 i.v. on days À14, À7 and À1, etoposide 2 g/m 2 i.v. over 4 h on day 0 followed by G-CSF 10 mg/kg s.c. daily starting on day 2. A previously described regimen of prophylactic antibiotics was administered to all patients. 8 Pheresis was initiated when, after its nadir, the WBC count reached 5000/ml and was continued in an attempt to collect 7 Â 10 6 CD34 þ cells/kg. Twenty liters of whole blood was routinely processed for each collection using horizon triple lumen catheters and Cobe machines. The SC product was not routinely evaluated for the presence of a monoclonal B-cell population. The preparative regimen consisted BU (14 mg/kg) administered orally (1 mg/kg every 6 h from days À9 to À5 for 14 doses beginning the evening of day À9), etoposide (60 mg/kg continuous i.v. infusion over 36 h from days À5 to À4) and cyclophosphamide (120 mg/kg) i.v. in two divided doses on days À3 and À2.
9 Auto-SCs were infused on day 0. All patients received G-CSF 480 mg i.v. daily beginning on day þ 5 and continuing until the ANC reached 500/ml and standard supportive care.
Statistical methods
The addition of rituximab to the MR was considered problematic if it reduced the CD34 þ cell yield by more than 50% relative to VPG. Power calculations indicated that 27 patients per MR were needed to have 80% power to detect this difference using a 5% level of significance.
Continuous variables are summarized as the median and range and compared among MRs using the Wilcoxon rank-sum test. Categorical variables are summarized as frequency counts and percentages and compared using the w 2 test. Noting the longer interval between the last cycle of salvage chemotherapy and the administration of etoposide in the RVPG arm, rank analysis of covariance was used to determine if CD34 þ cell yield differed among MRs after adjusting for this interval.
Analyses were performed using SAS software (SAS Institute, Inc., Cary, NC, USA). All statistical tests were two sided and (Po0.05) was used to indicate statistical significance.
Results
Seventy-six patients were enrolled between May 2000 and April 2005. Twenty-one (11 VPG and 10 RVPG) were removed from the study before receiving the assigned MR and were not evaluable: 10 because of the progression of lymphoma, three because of the cardiopulmonary disease and two by patient choice; in six, the reason was not documented. Fifty-five patients (28 RVPG and 27 VPG) received the assigned MR.
Patient and disease characteristics did not differ significantly between the two groups (Table 1) . Histologic subtypes were similar in the two groups (P ¼ 0.431) with diffuse large B-cell lymphoma predominant (20/28 RVPG, 15/27 VPG). The results of mobilization in the two groups are shown in Table 2 . The median number of days of pheresis was 3 (range 2-10) for the RVPG group and 4 (range 2-10) for the VPG group (P ¼ 0.13). One RVPG and four VPG patients collected o2.0 Â 10 6 CD34 þ cells/kg (P ¼ 0.15). Significantly more CD34 þ cells were collected during the first two days (median 7.9 Â 10 6 vs 0.9 Â 10 6 /kg, P ¼ 0.042) of pheresis and in total (median 9.9 Â 10 6 vs 5.6 Â 10 6 /kg, P ¼ 0.021) from the RVPG patients. After randomization, RVPG patients received rituximab 14 days before etoposide. Therefore, the interval between the last cycle of salvage chemotherapy and the administration of etoposide was longer (median 46 days vs 31 days) in the RVPG arm (Po0.001). After adjusting for the interval from last chemotherapy to etoposide administration, the RVPG group collected significantly more total CD34 þ cells (P ¼ 0.028), but the number of CD34 þ cells collected on the first two days (P ¼ 0.07) was not significantly different. After etoposide administration, the number of days with ANC o500/mm 3 (median 6 days vs 5 days, P ¼ 0.54), the percentage of patients with febrile neutropenia (25 vs 33%, P ¼ 0.50) and the number of platelet transfusions required per patient (median 1 vs 2, P ¼ 0.41) were not significantly different for the RVPG patients and the VPG patients respectively.
Overall, 50 patients (27 RVPG and 23 VPG) received the assigned MR, collected at least 2 Â 106 CD34 þ cells/kg, and proceeded to AHSCT. The median number of CD34 þ cells/kg infused was 9.5 Â 10 6 in the RVPG arm and 7.2 Â 10 6 in the VPG arm (P ¼ 0.09). The median number of days after transplantation until the ANC reached 500/mm 3 was 10 in both arms (P ¼ 0.08). The median days until platelets reached 20 000/mm 3 (RVPG 16 vs VPG 17, P ¼ 0.43), and median length of hospitalization (21 days in both arms, P ¼ 0.23) were similar in the two groups.
One patient in each group died within 100 days of transplantation and four in each group died within 6 months of transplantation. One RVPG patient developed transient neutropenia 3 months after transplantation. The percentage of patients with hypogammaglobulinemia (IgG o600 mg/100 ml) before (41% RVPG vs 38% VPG, P ¼ 0.83), 6 weeks after (60% RVPG vs 56% VPG, P ¼ 0.77) and 6 months after transplantation (54% RVPG vs 42% VPG, P ¼ 0.54) was not significantly different between the two groups (Table 3) .
Discussion
Contamination of the autograft by lymphoma cells may contribute to relapse after AHSCT. 10, 11 The use of rituximab to purge circulating lymphoma cells from blood before collection for AHSCT has generated considerable interest.
1-6,12,13 A randomized comparison found that although both methods effectively eliminate B cells, in vivo purging with rituximab was associated with more rapid recovery of neutrophils and platelets after transplantation than ex vivo purging by CD34 þ cell selection. 12 Nonrandomized studies have yielded mixed results as to whether rituximab might compromise the yield of PBSCs and hematopoietic recovery after autotransplantation.
1-6
Patients who fail to mobilize adequate numbers of CD34 þ cells with initial mobilization attempts have limited success with subsequent attempts that are also costly. [14] [15] [16] [17] Further, difficult SC mobilization predicts a poor outcome. Lastly, serious infections because of delayed B-cell recovery and late-onset neutropenia have been reported with post-transplant rituximab. [18] [19] [20] The potential negative impact of rituximab on mobilization provided the impetus for this study. This is the first prospectively randomized trial of rituximab before mobilization of PBSC. It demonstrates no adverse consequence of rituximab administration on CD34 þ cell yield, hematopoietic recovery or Ig levels after transplantation. There were no differences in clinical characteristics or before treatment of patients that might account for this.
The longer interval from the last salvage chemotherapy to the administration of etoposide in the RVPG patients may have enhanced PBSC collection. Repeated courses of myelotoxic drugs induce SC damage 21, 22 and some chemotherapeutic agents transiently impair hematopoietic progenitor mobilization. 23 The influence of the interval between earlier chemotherapy and mobilization; however, has attracted little attention in this heavily studied field. Trials of PBSC mobilization, including those with rituximab, fail to define or discuss this interval. Longer intervals between earlier chemotherapy and mobilization might enhance mobilization, but may increase risk of disease progression and contamination of the harvested SC product. The administration of rituximab might permit extension of this interval and thereby promote better SC mobilization.
Most importantly, rituximab did not impair CD34 þ cell yield nor hematopoeitic recovery after transplantation. Rituximab administration before etoposide and stem collection was not associated with any clinically significant short or long-term complications. Whether rituximab before PBSC mobilization improves freedom from progression or overall survival awaits larger prospective studies powered to address this important issue. 
